{"id":"alks-9072-low","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Constipation"},{"rate":null,"effect":"Withdrawal symptoms"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"ALKS 9072 binds to mu opioid receptors with partial agonist activity, providing sufficient receptor stimulation to prevent withdrawal and reduce drug-seeking behavior while maintaining a ceiling effect that limits euphoria and overdose risk. This mechanism is similar to buprenorphine but represents a distinct molecular entity being developed by Alkermes for opioid use disorder treatment.","oneSentence":"ALKS 9072 is a mu opioid receptor partial agonist designed to treat opioid use disorder by reducing cravings and withdrawal symptoms.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:00:45.060Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Opioid use disorder"}]},"trialDetails":[{"nctId":"NCT01626456","phase":"PHASE3","title":"A Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070)","status":"COMPLETED","sponsor":"Alkermes, Inc.","startDate":"2012-06","conditions":"Schizophrenia","enrollment":478},{"nctId":"NCT01493726","phase":"PHASE1","title":"A Study of ALKS 9072 in Subjects With Chronic Stable Schizophrenia","status":"COMPLETED","sponsor":"Alkermes, Inc.","startDate":"2011-12","conditions":"Schizophrenia","enrollment":88},{"nctId":"NCT01895452","phase":"PHASE3","title":"An Extension of a Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070)","status":"COMPLETED","sponsor":"Alkermes, Inc.","startDate":"2013-07","conditions":"Schizophrenia","enrollment":291}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"ALKS 9072, Low","genericName":"ALKS 9072, Low","companyName":"Alkermes, Inc.","companyId":"alkermes-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ALKS 9072 is a mu opioid receptor partial agonist designed to treat opioid use disorder by reducing cravings and withdrawal symptoms. Used for Opioid use disorder.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}